Table 3.
Cox regression analysis of progression-free-survival in hepatocellular carcinoma patients
| Variables | Subset | HR (95%CI) | P value |
| Univariate analysis (n = 213) | |||
| Age (yr) | < 49 vs ≥ 49 | 1.153 (0.834-1.596) | 0.389 |
| Sex | Female vs male | 1.464 (0.770-2.783) | 0.245 |
| AFP (ng/mL) | < 400 vs ≥ 400 | 1.219 (0.879-1.690) | 0.236 |
| Grade | I + II vs III + IV | 1.335 (0.966-1.847) | 0.080 |
| Stage | I + II vs III + IV | 1.926 (1.304-2.845) | 0.001 |
| ALK/CNG | Yes vs no | 1.598 (1.001 -2.552) | 0.049 |
| Child-Pugh classification | A vs B + C | 2.165 (1.300-3.608) | 0.002 |
| HBV DNA | Positive vs negative | 1.067 (0.771-1.476) | 0.696 |
| Postoperative plateletcount | < 100 × 109/L vs ≥ 100 × 109/L | 1.267 (0.839-1.914) | 0.260 |
| Multivariate analysis (n = 213) | |||
| Stage | I + II vs III + IV | 1.775 (1.179-2.673) | 0.006 |
| ALK/CNG | Yes vs no | 1.596 (1.008-2.526) | 0.046 |
| Child-Pugh classification | A vs B + C | 1.744 (1.021-2.979) | 0.042 |
ALK/CNG: Anaplastic lymphoma kinase copy number gain; AFP: Alpha fetoprotein; HBV: Hepatitis B virus.